There are more vaccines around the world that are in the works these days along with various potential treatments for the novel coronavirus.
Now, it’s been revealed by CNBC that Johnson & Johnson’s potential coronavirus vaccine prevented severe illness in a small group of Syrian golden hamsters.
It seems that J&J vaccinated the animals with a single dose and then it exposed the rodents to the virus four weeks later, according to the info from the company.
The vaccine was successful
It’s been reported that the vaccine-elicited neutralizing antibodies that experts believe are necessary to build immunity to the virus in the hamsters that have been vaccinated.
The vaccinated hamsters also seemed to lose less weight compared to unvaccinated hamsters and did not see any severe clinical disease such as pneumonia or mortality, according to the same study.
The exciting results have been published in the medical journal Nature Medicine.
“This pre-clinical study further validates our confidence in our SARS-CoV-2 vaccine candidate,” J&J’s Chief Scientific Officer Paul Stoffels said in a press release.
“With our Phase 3 trials planned to start this month, we remain committed to expanding our manufacturing and distribution capabilities to enable global access to our SARS-CoV-2 vaccine candidate should it prove to be safe and effective in humans.”
It’s also important to highlight the fact that the successful results in rodents do not necessarily mean that the vaccine will provide the same level of protection in humans as well.
A viable vaccine will be available this year
“I believe that by the time we get to the end of this calendar year that we will feel comfortable that we do have a safe and effective vaccine,” Fauci, the director of the National Institute of Allergy and Infectious Diseases, said on NBC’s “TODAY” this week.